Atlas Trials

Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma

Clinical trial NCT03126630 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03126630
Sponsor
National Cancer Institute (NCI)
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Pleural Malignant Mesothelioma
Start date
2018-10-04
Primary completion
2023-05-04
Enrollment
49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.